Leo puts target on Dupixent in US as FDA clears tralokinumab
pharmaphorum
DECEMBER 29, 2021
IL-13 inhibitor tralokinumab has been cleared by the US regulator as Adbry as a treatment for moderate-to-severe atopic dermatitis in adults who can’t control symptoms using topical prescription therapies. The post Leo puts target on Dupixent in US as FDA clears tralokinumab appeared first on.
111 
Let's personalize your content